Core Insights - Agios Pharmaceuticals announced that its sickle cell drug achieved one of its two primary objectives in a late-stage study involving patients aged 16 and older, but did not demonstrate a statistically significant reduction in the other primary endpoint [1] Group 1: Study Results - The drug met one of the two main goals in the late-stage study [1] - The study involved patients aged 16 and older [1] - The drug failed to show a statistically significant reduction in the second primary endpoint [1]

Company Performance - Pfizer's drug for sickle cell disease failed a phase three trial [1] - The failure impacts Pfizer's investment in Global Blood Therapeutics, acquired for approximately $5 billion [1] - Pfizer had to pull Oxbrida from the market due to safety concerns [2] - One remaining drug from the Global Blood Therapeutics acquisition is in phase three development [2][3] Industry Dynamics - Sickle cell disease primarily affects black people, with limited treatment options available [4] - Global Blood Therapeutics was developing easier-to-take pills and drugs for sickle cell disease [4] - Existing treatments, like gene editing, can be intensive, requiring hospitalization [5] - There is hope that Pfizer and other companies can develop easier treatments for patients [5]